NICE Recommends Sanofi's New Treatment Dupixent(R) - (dupilumab) for Adults with Moderate to Severe Atopic Dermatitis in England[1]

02:04 EDT 22 Jun 2018 | FinanzNachrichten

GUILDFORD, England, June 22, 2018 /PRNewswire/ -- - Positive recommendation for Dupixent[R] (dupilumab) in Final Appraisal Determination (FAD) paves the way for the first targeted biologic for adu...

More From BioPortfolio on "NICE Recommends Sanofi's New Treatment Dupixent(R) - (dupilumab) for Adults with Moderate to Severe Atopic Dermatitis in England[1]"